Learn More
Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a(More)
Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, a 'pure' heart rate-lowering drug would(More)
ESC Committee for Practice Guidelines (CPG): Alec Vahanian (Chairperson) (France), John Camm (UK), Raffaele De Caterina (Italy), Veronica Dean (France), Kenneth Dickstein (Norway), Christian Funck-Brentano (France), Gerasimos Filippatos (Greece), Irene Hellemans (The Netherlands), Steen Dalby Kristensen (Denmark), Keith McGregor (France), Udo Sechtem(More)
We would like to thank Dr Veselka for his interest in our work and appreciate the opportunity to respond to his letter. Our article illustrated that successful alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) led to significant and sustained improvement (up to 2-year follow-up) in echocardiographic measures of diastolic(More)
OBJECTIVES We sought to assess the impact of intermittent atrial fibrillation (AF) on health-related quality of life (QoL). BACKGROUND Intermittent AF is a common condition with little data on health-related QoL questionnaires to guide investigational therapies. METHODS Outpatients from four centers, with documented AF (n = 152), completed validated QoL(More)